{"DataElement":{"publicId":"3366758","version":"1","preferredName":"Lymphoma Treatment Administered Combination Pharmaceutical Agent Name","preferredDefinition":"Text term or code to represent the name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma.","longName":"3284249v1.0:3366679v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3284249","version":"1","preferredName":"Lymphoma Treatment Administered","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The act of having given something (e.g., a medication or test).","longName":"2475110v1.0:3284230v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2475110","version":"1","preferredName":"Lymphoma","preferredDefinition":"A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003","longName":"C3208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11901624-1EB2-3055-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-16","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-16","modifiedBy":"ONEDATA","dateModified":"2006-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3284230","version":"1","preferredName":"Therapeutic Procedure Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Given.","longName":"C49236:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD8D766D-1F24-B777-E040-BB89AD434B22","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-22","modifiedBy":"ONEDATA","dateModified":"2011-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD8DD9EE-E7BA-52F4-E040-BB89AD434398","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by S.Shakour and D.Reeves. mc 12/1/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3366679","version":"1","preferredName":"Combination Pharmaceutical Agent Name","preferredDefinition":"A collection of things that have been assembled together to form a new whole._A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._The words or language units by which a thing is known.","longName":"3366679v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CHOP-14","valueDescription":"14 Day CHOP Regimen","ValueMeaning":{"publicId":"3366680","version":"1","preferredName":"14 Day CHOP Regimen","longName":"3366680","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-723A-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1006E-7253-FDDD-E040-BB89AD437842","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CAP-BOP","valueDescription":"CAP-BOP","ValueMeaning":{"publicId":"3366681","version":"1","preferredName":"CAP-BOP","longName":"3366681","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, procarbazine, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BACOPP Regimen","conceptCode":"C9564","definition":"A chemotherapy regimen consisting of bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone that can be used for the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-725D-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1006E-7276-FDDD-E040-BB89AD437842","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"BACOP","valueDescription":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine","ValueMeaning":{"publicId":"3366683","version":"1","preferredName":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine","longName":"3366683","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine","conceptCode":"C9550","definition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-7283-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Corrected typo error in definition. mc 9/25/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1006E-729C-FDDD-E040-BB89AD437842","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"Single Agent Therapy (please specify)","valueDescription":"Single Agent","ValueMeaning":{"publicId":"3366701","version":"1","preferredName":"Single Agent","longName":"3366701","preferredDefinition":"Not accompanied by another or others.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5111-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-512A-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"Other Pharmaceutical Regimen (please specify)","valueDescription":"Other","ValueMeaning":{"publicId":"3241404","version":"1","preferredName":"Other","longName":"3241404","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A5D-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-513E-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"VACOP-B","valueDescription":"VACOP-B","ValueMeaning":{"publicId":"3366702","version":"1","preferredName":"VACOP-B","longName":"3366702","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VACOP-B Regimen","conceptCode":"C11343","definition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5149-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5162-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"ProMace-MOPP","valueDescription":"ProMace-MOPP","ValueMeaning":{"publicId":"3366703","version":"1","preferredName":"ProMace-MOPP","longName":"3366703","preferredDefinition":"A chemotherapy combination consisting of cyclophosphamide, doxorubicin, etoposide, mechlorethamine, methotrexate, prednisone, procarbazine, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE-MOPP Regimen","conceptCode":"C9679","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide (ProMACE) followed by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-516C-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5185-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"ProMace-CytaBOM","valueDescription":"ProMace-CytaBOM Regimen","ValueMeaning":{"publicId":"3366704","version":"1","preferredName":"ProMace-CytaBOM Regimen","longName":"3366704","preferredDefinition":"A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Alternating with CytaBOM Regimen","conceptCode":"C63460","definition":"A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-518F-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-51A8-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"MACOP-B","valueDescription":"MACOP-B Regimen","ValueMeaning":{"publicId":"3366705","version":"1","preferredName":"MACOP-B Regimen","longName":"3366705","preferredDefinition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MACOP-B Regimen","conceptCode":"C63457","definition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51B2-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-51CB-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"LNH-87","valueDescription":"LNH-87","ValueMeaning":{"publicId":"3366707","version":"1","preferredName":"LNH-87","longName":"3366707","preferredDefinition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACVBP Regimen","conceptCode":"C63446","definition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51F8-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5211-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"LNH-84","valueDescription":"LNH-84","ValueMeaning":{"publicId":"3366708","version":"1","preferredName":"LNH-84","longName":"3366708","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine Regimen","conceptCode":"C10783","definition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine that can be used for the treatment of lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-521B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5234-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"ICE + Rituxumab","valueDescription":"ICE Plus Rituxumab","ValueMeaning":{"publicId":"3366709","version":"1","preferredName":"ICE Plus Rituxumab","longName":"3366709","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-523E-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5257-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"ICE","valueDescription":"ICE Regimen","ValueMeaning":{"publicId":"3366711","version":"1","preferredName":"ICE Regimen","longName":"3366711","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5264-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-527D-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"High Dose Methotrexate w/Leucovorin","valueDescription":"High Dose Leucovorin Calcium/Methotrexate","ValueMeaning":{"publicId":"3366713","version":"1","preferredName":"High Dose Leucovorin Calcium/Methotrexate","longName":"3366713","preferredDefinition":"High; greater than normal in degree or intensity or amount.: The amount of medicine taken, or radiation given, at one time.: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leucovorin Calcium/Methotrexate Regimen","conceptCode":"C11823","definition":"A regimen consisting of leucovorin and methotrexate that can be used for the treatment of osteosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-528C-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-52A5-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"DA-EPOCH + Rituxumab","valueDescription":"Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin plus Rituximab","ValueMeaning":{"publicId":"3366714","version":"1","preferredName":"Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin plus Rituximab","longName":"3366714","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time. : The act of making necessary corrections or modifications.: A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Adjustment","conceptCode":"C49157","definition":"The act of making necessary corrections or modifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-52AF-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-52C8-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"DA-EPOCH","valueDescription":"Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin","ValueMeaning":{"publicId":"3366715","version":"1","preferredName":"Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin","longName":"3366715","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time. : The act of making necessary corrections or modifications.: A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adjustment","conceptCode":"C49157","definition":"The act of making necessary corrections or modifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-52D2-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-52EB-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"F-MACHOP","valueDescription":"5-Fluorouracil, Methotrexate with Leucovorin Rescue, Cytarabine, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","ValueMeaning":{"publicId":"3366716","version":"1","preferredName":"5-Fluorouracil, Methotrexate with Leucovorin Rescue, Cytarabine, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","longName":"3366716","preferredDefinition":"A chemotherapy regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"F-MACHOP Regimen","conceptCode":"C99697","definition":"A chemotherapy regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-52F5-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-530E-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CVP","valueDescription":"CVP Regimen","ValueMeaning":{"publicId":"3366718","version":"1","preferredName":"CVP Regimen","longName":"3366718","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine and prednisone used to treat indolent forms of non-Hodgkin's lymphoma; also used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CVP Regimen","conceptCode":"C9573","definition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-531B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5334-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CNOP","valueDescription":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","ValueMeaning":{"publicId":"3366722","version":"1","preferredName":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","longName":"3366722","preferredDefinition":"A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CNOP Regimen","conceptCode":"C63453","definition":"A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5367-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5380-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CHOP-21 + Rituximab","valueDescription":"CHOP Regimen 21 Day And Rituximab ","ValueMeaning":{"publicId":"3366723","version":"1","preferredName":"CHOP Regimen 21 Day And Rituximab ","longName":"3366723","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-538A-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-53A3-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CHOP-14 + Rituximab","valueDescription":"CHOP Regimen 14 Day And Rituximab ","ValueMeaning":{"publicId":"3366724","version":"1","preferredName":"CHOP Regimen 14 Day And Rituximab ","longName":"3366724","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-53AD-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-53C6-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CHOP + Etoposide","valueDescription":"CHOP Regimen And Etoposide","ValueMeaning":{"publicId":"3366725","version":"1","preferredName":"CHOP Regimen And Etoposide","longName":"3366725","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-53D4-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-53ED-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CHOP + Bleomycin","valueDescription":"CHOP Regimen And Bleomycin","ValueMeaning":{"publicId":"3366726","version":"1","preferredName":"CHOP Regimen And Bleomycin","longName":"3366726","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-53FB-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-5414-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"CHOP-21","valueDescription":"21 Day CHOP Regimen","ValueMeaning":{"publicId":"3366727","version":"1","preferredName":"21 Day CHOP Regimen","longName":"3366727","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5422-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7C1BF06-543B-30E6-E040-BB89AD436407","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","deletedIndicator":"No"},{"value":"M-BACOP","valueDescription":"M-BACOP","ValueMeaning":{"publicId":"3366706","version":"1","preferredName":"M-BACOP","longName":"3366706","preferredDefinition":"A chemotherapy regimen consisting of methotre xate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M-BACOP Regimen","conceptCode":"C99696","definition":"A chemotherapy regimen consisting of methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51D5-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7D59407-7E07-B72A-E040-BB89AD432902","beginDate":"2012-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-31","modifiedBy":"ONEDATA","dateModified":"2012-01-31","deletedIndicator":"No"},{"value":"C-MOPP","valueDescription":"COPP Regimen","ValueMeaning":{"publicId":"3368104","version":"1","preferredName":"COPP Regimen","longName":"3368104","preferredDefinition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin's lymphoma. Also used for the treatment of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COPP Regimen","conceptCode":"C9567","definition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7D59407-7E14-B72A-E040-BB89AD432902","latestVersionIndicator":"Yes","beginDate":"2012-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B7D59407-7E2D-B72A-E040-BB89AD432902","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-31","modifiedBy":"ONEDATA","dateModified":"2012-01-31","deletedIndicator":"No"},{"value":"Vanderbilt regimen + Rituximab","valueDescription":"Cyclophosphamide Etoposide Vincristine Bleomycin Methotrexate Doxorubicin Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3590031","version":"1","preferredName":"Cyclophosphamide Etoposide Vincristine Bleomycin Methotrexate Doxorubicin Rituximab Treatment Regimen","longName":"3590031","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04): An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA000461-2AEA-8373-E040-BB89AD437404","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA000461-2B03-8373-E040-BB89AD437404","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","deletedIndicator":"No"},{"value":"HyperCVAD-Mtx/AraC + Rituximab","valueDescription":"HyperCVAD/HD MTX AraC Regimen Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3590033","version":"1","preferredName":"HyperCVAD/HD MTX AraC Regimen Rituximab Treatment Regimen","longName":"3590033","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) administered on a hyperfractionated schedule, followed by high dose methotrexate and cytarabine, and used to treat Burkitt's lymphoma.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Alternating with High-dose MTX AraC Regimen","conceptCode":"C63472","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, alternating with high-dose cytarabine and methotrexate, that can be used in the treatment of acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA000461-2B12-8373-E040-BB89AD437404","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA000461-2B2B-8373-E040-BB89AD437404","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","deletedIndicator":"No"},{"value":"CODOX + Rituximab","valueDescription":"Cyclophosphamide/Doxorubicin/Vincristine Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3590034","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Vincristine Rituximab Treatment Regimen","longName":"3590034","preferredDefinition":"A chemotherapy combination consisting of cyclophosphamide, doxorubicin, and vincristine.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Doxorubicin/Vincristine","conceptCode":"C9540","definition":"A chemotherapy combination consisting of cyclophosphamide, doxorubicin, and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA000461-2B39-8373-E040-BB89AD437404","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA000461-2B52-8373-E040-BB89AD437404","beginDate":"2012-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FCA3FDC-7260-361E-E053-F662850ABFBD","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"CE (Cisplatin and Etoposide)","valueDescription":"Cisplatin and Etoposide","ValueMeaning":{"publicId":"3645446","version":"1","preferredName":"Cisplatin and Etoposide","longName":"3645446","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0D2E961-F42B-6B4F-E040-BB89AD431228","latestVersionIndicator":"Yes","beginDate":"2012-12-14","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FCA3FDC-7275-361E-E053-F662850ABFBD","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"CAV (Cyclophosphamide, Adriamycin and Vincristin)","valueDescription":"CAV (Cyclophosphamide, Adriamycin and Vincristin)","ValueMeaning":{"publicId":"5544377","version":"1","preferredName":"CAV (Cyclophosphamide, Adriamycin and Vincristin)","longName":"5544377","preferredDefinition":"CAV (Cyclophosphamide, Adriamycin and Vincristin)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCA3FDC-7280-361E-E053-F662850ABFBD","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FCA3FDC-7299-361E-E053-F662850ABFBD","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Carboplatin + Paclitaxel","valueDescription":"Carboplatin And Paclitaxel","ValueMeaning":{"publicId":"5544378","version":"1","preferredName":"Carboplatin And Paclitaxel","longName":"5544378","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCA3FDC-72A7-361E-E053-F662850ABFBD","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FCA3FDC-72C0-361E-E053-F662850ABFBD","beginDate":"2016-10-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435016","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B9F7-9264-25C9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3366678","version":"1","preferredName":"Combination Pharmacologic Substance Name","preferredDefinition":"A collection of things that have been assembled together to form a new whole.:A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.:The words or language units by which a thing is known.","longName":"C61517:C1909:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-720F-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"ONEDATA","dateModified":"2012-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-7220-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"COOPERM","dateModified":"2016-10-26","changeDescription":"Created and released for TCGA per request and approval by B.McClure-Shimel. mc 1/30/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"5655939","version":"1","longName":"BLGSP (Burkitt Lymphoma Genome Sequencing Project)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000268","version":"1","longName":"Initial Treatment and Followup Form","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Pharmaceutical Regimen","type":"Preferred Question Text","description":"Pharmaceutical Regimen","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C2092F-48B7-097B-E040-BB89AD432E54","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/31/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}